The evolution in melanoma treatment as a reflection of precision-oriented medicine (Review)

Kushnir,Igal; Merimsky,Ofer

doi:10.3892/ol.2012.1065

The evolution in melanoma treatment as a reflection of precision-oriented medicine (Review)

Authors:
- Igal Kushnir
- Ofer Merimsky
View Affiliations

Affiliations: Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv 64239, Israel
Published online on: December 5, 2012 https://doi.org/10.3892/ol.2012.1065
Pages: 424-426

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Until recently, metastatic melanoma was a disease with limited treatment options and a poor prognosis. Dacarbazine was accepted as the standard treatment for melanoma in the 1970s, and despite inducing an overall survival of approximately 7.4 months, it remained so until relatively recently. In the last few years, significant advances in the molecular understanding of this disease have facilitated the development of novel and promising drugs. Precision-oriented medicine is currently revolutionizing the practice of oncology. Targeted therapies have demonstrated great potential in treating melanoma and various other types of cancer, including breast, colorectal and non-small cell lung cancer. Here, we review the evolution of melanoma treatment from single-agent chemotherapy to combination therapy, the emergence of immunotherapy in melanoma and the development of targeted therapies, such as the use of the BRAF inhibitor as a treatment agent. The ability to treat melanoma according to the fingerprint of the tumor reflects an overall change in the practice of oncology.

View Figures

View References

1.	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
2.	Hayat MJ, Howlader N, Reichman ME and Edwards BK: Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 12:20–37. 2007. View Article : Google Scholar : PubMed/NCBI
3.	Luce JK: Chemotherapy of malignant melanoma. Cancer. 30:1604–1615. 1972. View Article : Google Scholar : PubMed/NCBI
4.	Benjamin RS: Chemotherapy of malignant melanoma. World J Surg. 3:321–328. 1979. View Article : Google Scholar
5.	Huncharek M, Caubet JF and McGarry R: Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res. 11:75–81. 2001. View Article : Google Scholar
6.	Legha SS, Ring S, Papadopoulos N, Plager C and Benjamin R: A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer. 64:2024–2029. 1989. View Article : Google Scholar : PubMed/NCBI
7.	Atkins MB, Hsu J, Lee S, et al: Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 26:5748–5754. 2008.
8.	Chapman PB, Einhorn LH, Meyers ML, et al: Phase III multi-center randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 17:2745–2751. 1999.PubMed/NCBI
9.	Lewis MG: Possible immunological factors in human malignant melanoma in Uganda. Lancet. 2:921–922. 1967. View Article : Google Scholar : PubMed/NCBI
10.	Tefany FJ, Barnetson RS, Halliday GM, McCarthy SW and McCarthy WH: Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Inves Dermatol. 97:197–202. 1991. View Article : Google Scholar : PubMed/NCBI
11.	Ram M and Shoenfeld Y: Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality? Ann N Y Acad Sci. 1110:410–425. 2007. View Article : Google Scholar : PubMed/NCBI
12.	Merimsky O, Shoenfeld Y and Fishman P: The clinical significance of antityrosinase antibodies in melanoma and related hypopigmentary lesions. Clin Rev Allergy Immunol. 16:227–236. 1998. View Article : Google Scholar : PubMed/NCBI
13.	Fishman P, Azizi E, Shoenfeld Y, et al: Vitiligo autoantibodies are effective against melanoma. Cancer. 72:2365–2369. 1993. View Article : Google Scholar : PubMed/NCBI
14.	Atkins MB, Lotze MT, Dutcher JP, et al: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 17:2105–2116. 1999.PubMed/NCBI
15.	Komenaka I, Hoerig H and Kaufman HL: Immunotherapy for melanoma. Clin Dermatol. 22:251–265. 2004. View Article : Google Scholar
16.	Hodi FS, O’Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar
17.	Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature. 417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
18.	Sosman JA, Kim KB, Schuchter L, et al: Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 366:707–714. 2012. View Article : Google Scholar : PubMed/NCBI
19.	Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 364:2507–2516. 2011. View Article : Google Scholar : PubMed/NCBI
20.	Curtin JA, Busam K, Pinkel D and Bastian BC: Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 24:4340–4346. 2006. View Article : Google Scholar : PubMed/NCBI
21.	Hodi FS, Friedlander P, Corless CL, et al: Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 26:2046–2051. 2008. View Article : Google Scholar : PubMed/NCBI